Loading company…
Mnemo Therapeutics develops cell therapies using a platform for identifying antigen classes.
Founded in 2019 and based in Paris, France, Mnemo Therapeutics develops cell therapies using its EnfiniT drug discovery platform to identify antigen classes. Alain Maiore founded the company. In June 2021, it raised EUR 75 million in Series A funding to advance its platform and CAR T cell therapy research with Institut Curie and Memorial Sloan Kettering Cancer Center.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in